Published: 2019-10-24

Efficacy of autologous platelet rich plasma versus regular dressing in chronic wounds

Asif ., N. Chandramouli


Background: Chronic wounds are a frequent problem and pose a heavy burden to the service provider. Platelet extract containing several growth factors used on chronic wounds has shown impressive results in both healing percentage and time for epithelisation. Platelet extract from the patient’s own blood has been used in trials as a cheap and equally effective alternative to commercial platelet gels. The aim of the study was to demonstrate the therapeutic role of autologous platelet rich plasma (APRP) in epithelialisation and reduction in size of chronic wounds of lower limb.

Methods: It is a case control study, conducted at Sri Adichunchanagiri Hospital and Research Centre, B.G. Nagara, Karnataka. Conducted during January 2017 to June 2018 this study consisted of 30 patients with chronic ulcers between the age group of 18-80 years, with duration of ulcer ranging from 12 to 26 weeks. After obtaining consent they were randomly allotted into control and test groups with 15 patients each. Control group patients were treated with conventional dressing and in test group APRP dressing was done. Later percentage decrease in wound size was assessed.

Results: Ulcer size decreased significantly (p<0.0001) in test group compared to control group. No unwanted effects or complications noted.

Conclusions: APRP is a safe and effective treatment modality for chronic non-healing ulcers. It enhances healing and also decreases the associated cost and morbidity. Further research and randomized controlled clinical trials on larger patient population are necessary to validate the results.


Autologous platelet rich plasma, Chronic wounds, Ulcer healing

Full Text:



Saltmarche AE. Low level laser therapy for healing acute and chronic woundsthe extendicare experience. Int Wound J. 2008;5(2):351-60.

Driver R, Hanft J, Fylling P, Beriou JM; Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet rich plasma for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52(6):68-87.

Andia I, Abate M. Platelet-rich plasma: underlying biology and clinical correlates. Regen Med. 2013;8(5):645-58.

Agale SV. Chronic leg ulcers: epidemiology, aetiopathogenesis, and management. Ulcers. 2013;413604:1-9.

Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers.Cochrane Database Syst Rev. 2006;(3):CD001103.

Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol. 1992;18(7):604-6.

Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. Cochrane Database Syst Rev. 2007;(1):CD005486.

Lacci MK, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med. 2010;83(1):1-9.

Everts PA, Knape JT, Weibrich G, Schönberger JP, Hoffmann J, Overdevest EP, et al. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006;38(2):174-87.

Gottrup F, Karlsmark T. Current management of wound healing. G Ital Dermatol Venereol. 2009;144(3):217-28.

Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225-8.

Driver VR, Hanft J, Fylling CP, Beriou JM. Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52(6):68-70.

Suresh DH, Suryanarayan S, Sarvainamurthy S, Puvvadi S. Treatment of a Non-healing diabetic foot ulcer with platelet rich plasma. J Cutan Aesthet Surg. 2014;7(4):229-31.

Carter MJ, Fylling CP, Parnell LK. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty. 2011;11:e38.

Tzeng YS, Deng SC, Wang CH, Tsai JC, Chen TM, Burnouf T. Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series. Biotechnol Res Int. 2013;837620:9.

Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds: Successful treatment with autologous platelet-derived wound healing factors (PDWHF) Ann Surg. 1986;204:322-30.

Singh RP, Marwaha N, Malhotra P, Dash S. Quality assessment of platelet concentrates prepared by platelet rich plasma platelet concentrate, buffy coat poor platelet concentrate (BCPC) and apheresis PC method. Asian J Transfus Sci. 2009;3(2):86-94.

Driver VR, Hanft J, Fylling CP, Beriou JM. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52(6):68-74.

Frykberg RG, Driver VR, Carman D, Lucero B, Borris-Hale C, Fylling CP, et al. Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: a prospective case series. Ostomy Wound Manage. 2010;56:36-44.

Steenvoorde P, van Doorn LP, Naves C, Oskam J. Use of autologous plateletrich fibrin on hard-to-heal wounds. J Wound Care. 2008;17:603.

Kakudo N, Kushida S, Ogura N, Hara T, Suzuki K. The use of autologous platelet rich plasma in the treatment of intractable skin ulcer. Open J Reg Med. 2012;1:29-32.

Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III leucocyte activation: a new feature for platelet. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(3):e51-5.